Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dar Al Dawa Development and Investment Days Payable?
Dar Al Dawa Development and InvestmentAMM:DADI 77 Days Payable is 188.01 as of Jun. 2026, which is 114% above its 10-year median of 87.85. GuruFocus rates AMM:DADI with a GF Score™ of 77/100 and a GF Value™ of JOD1.03 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, Dar Al Dawa Development and Investment ranks better than 76.43% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment Days Payable Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's Days Payable distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's Days Payable falls into.
Dar Al Dawa Development and Investment Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment (AMM:DADI) has a Days Payable of 188.01 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 114% above median its historical median of 87.85. Over the past decade, Dar Al Dawa Development and Investment's Days Payable has ranged from 64.54 to 152.35. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #218 out of 925 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Dar Al Dawa Development and Investment's Days Payable too high?
Dar Al Dawa Development and Investment's current Days Payable of 188.01 is 114% above median its 10-year median of 87.85. Over the past 10 years, this metric has ranged from a low of 64.54 to a high of 152.35. The Drug Manufacturers industry median Days Payable is 88.94. Dar Al Dawa Development and Investment's value of 188.01 is 111.4% above this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #218 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #218 out of 925 companies for Days Payable. This places Dar Al Dawa Development and Investment in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.94. Dar Al Dawa Development and Investment's value of 188.01 is 111.4% above this benchmark. Historically, Dar Al Dawa Development and Investment's own Days Payable has ranged from 64.54 to 152.35 over the past decade. While the company's 10-year median is 87.85 vs. the industry median of 88.94, Dar Al Dawa Development and Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.94, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current Days Payable of 188.01 is 111.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current Days Payable is 188.01, which is 114% above median its own 10-year median of 87.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.03, compared to a current price of JOD1.17 — trading 13.6% above its estimated fair value. The current Days Payable is 188.01, which is 114% above median its 10-year median of 87.85 and 111.4% above the Drug Manufacturers industry median of 88.94. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current Days Payable is 188.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.17 is trading 13.6% above its estimated GF Value™ of JOD1.03.
GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.
Key valuation signals for AMM:DADI:
Days Payable: 188.01 (114% above median its 10-year median of 87.85)
GF Value™: JOD1.03 vs. price of JOD1.17 (13.6% above fair value)
Industry Position: 111.4% above the Drug Manufacturers median (#218 of 925)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
